(Q36407429)

14 August 2017

1 reference

title

Tipifarnib: farnesyl transferase inhibition at a crossroads (English)

1 reference

14 August 2017

Ruben A Mesa

1

1 reference

14 August 2017

1 March 2006

1 reference

Expert Review of Anticancer Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

3

1 reference

14 August 2017

313-319

1 reference

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

RAS and leukemia: from basic mechanisms to gene-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Protein prenylation: from discovery to prospects for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Farnesyl transferase inhibitors in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.3.313

21 January 2018

Identifiers

DOI

10.1586/14737140.6.3.313

1 reference

14 August 2017

1 reference

PubMed ID

16503848